Tag Archives: Bioverativ

Sanofi: the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for Sanofi’s acquisition of Bioverativ has expired

PARIS, 26-Feb-2018 — /EuropaWire/ — Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Bioverativ Inc. (“Bioverativ”, NASDAQ: BIVV) has expired. On February 7, … Read the full press release